Enrolling Clinical Research Studies
Type 2 Diabetes, Hypertension and established Cardiovascular Disease
Type 2 Diabetes and Cardiovascular Risk
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, arterial hypertension and established cardiovascular disease